Cellectar Biosciences (CLRB) Price & Analysis

Q: What was Cellectar Biosciences’s price range in the past 12 months?

Cellectar Biosciences lowest stock price was $3.17 and its highest was $66.00 in the past 12 months.

Q: What is Cellectar Biosciences’s market cap?

Cellectar Biosciences’s market cap is $10.69M.

Q: When is Cellectar Biosciences’s upcoming earnings report date?

Cellectar Biosciences’s upcoming earnings report date is Mar 18, 2026 which is in 128 days.

Q: Is Cellectar Biosciences overvalued?

According to Wall Street analysts Cellectar Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does Cellectar Biosciences pay dividends?

Cellectar Biosciences does not currently pay dividends.

Q: What is Cellectar Biosciences’s EPS estimate?

Cellectar Biosciences’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Cellectar Biosciences have?

Cellectar Biosciences has 3,192,040 shares outstanding.

Q: Which hedge fund is a major shareholder of Cellectar Biosciences?

Currently, no hedge funds are holding shares in CLRB

Compare

1,433 Followers

CLRB Stock Chart & Stats

$3.39

-$0.03(-9.33%)

At close: Jan 08 4:00 PM EST

$3.39

-$0.03(-9.33%)

Day’s Range― - ―

52-Week Range$3.17 - $66.00

Previous CloseN/A

Volume1.30M

Average Volume (3M)105.19K

Market Cap

$10.69M

Enterprise Value$2.75M

Total Cash (Recent Filing)$11.04M

Total Debt (Recent Filing)$453.51K

Price to Earnings (P/E)―

Beta1.48

Next Earnings

Mar 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding3,192,040

10 Day Avg. Volume157,484

30 Day Avg. Volume105,193

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)0.96

Price to Sales (P/S)0.00

P/FCF Ratio-0.29

Enterprise Value/Market Cap0.26

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-0.07

Forecast

1Y Price Target

$15.20

Price Target Upside348.38% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Regulatory ApprovalCellectar recently held a meeting with the FDA, which confirmed a clear path to accelerated approval for Iopofosine-131 in Waldenstrom’s macroglobulinemia.

Strategic PartnershipsCellectar remains in active discussions with potential partners to out-license Iopofosine-131 in Waldenstrom’s macroglobulinemia (WM).

Bears Say

Financial PerformanceCellectar reported 2Q25 results with a net loss of ($5.4M) and ended the period with $11.0M in cash.

Program Development UncertaintyCellectar's radiopharma pipeline, including the P1-ready assets CLR-121225 and CLR-121125, were the key drivers for CLRB. As the company now seeks strategic alternatives for its assets, there is significant uncertainty regarding the future development of these programs.

Cellectar Biosciences News

Cellectar Biosciences receives RPDD from U.S. FDA for iopofosine I 131

Cellectar Biosciences (CLRB) announced the U.S. Food and Drug Administration, FDA, has granted rare pediatric drug designation, RPDD,...

14d ago

CLRB

Cellectar Biosciences files to sell 2.1M shares of common stock for holders

17:27 EDT Cellectar Biosciences (CLRB) files to sell 2.1M shares of common stock for holders Published first on...

21d ago

CLRB

Cellectar Biosciences presents posters at AACR on CLR 121225, CLR 225

Cellectar Biosciences (CLRB) announced that Jarrod Longcor, chief operating officer of Cellectar, presented positive preclinical data in a...

27d ago

CLRB

Cellectar Biosciences Inc (CLRB) Q3 Earnings Cheat Sheet

Cellectar Biosciences Inc (CLRB) is scheduled to report 3rd quarter earnings on 10/30/2025. Regarding Q3 estimates, Wall Street...

13d ago

CLRB

Cellectar Biosciences Raises $5.8M Through Warrant Exercise

Cellectar Biosciences ( ($CLRB) ) has provided an update. On October 7, 2025, Cellectar Biosciences entered into warrant...

1M ago

CLRB

Cellectar Biosciences enters agreements to raise $5.8M

Cellectar Biosciences (CLRB) announced an agreement between the company and several institutional investors to exercise certain existing warrants...

1M ago

CLRB

EMA news ‘a substantial positive catalyst’ for Cellectar, says Oppenheimer

Oppenheimer notes Cellectar Biosciences (CLRB) announced receipt of feedback from the Scientific Advice Working Party of the European...

1M ago

CLRB

Cellectar Biosciences Receives EMA Advice on Drug Filing

Cellectar Biosciences ( ($CLRB) ) has provided an update. On October 6, 2025, Cellectar Biosciences announced that the...

1M ago

CLRB

Cellectar says EMA confirms eligibility to file for CMA for iopofosine I 131

Cellectar Biosciences (CLRB) announced that after a scientific advice procedure, the Scientific Advice Working Party of the European...

1M ago

CLRB

Cellectar Biosciences says Iopofosine I 131 well tolerated in case studies

Cellectar Biosciences (CLRB) announced that Jarrod Longcor, COO of Cellectar, delivered an oral presentation followed by a 55-minute...

1M ago

CLRB

Cellectar, Evestia entered into agreement for Phase 1b study of CLR 125

Cellectar Biosciences (CLRB) and Evestia Clinical have entered into an agreement whereby Evestia will provide Cellectar with full...

2M ago

CLRB

Cellectar Biosciences, ITM enter supply agreement for GMP-grade Ac-225

Cellectar Biosciences (CLRB) and ITM Isotope Technologies Munich announced a supply agreement for Actinium-225, Ac-225. The agreement will...

2M ago

CLRB

Cellectar to attend at Oppenheimer Targeted Radiopharmaceuticals summit

While participating at this radiopharmaceutical therapy summit, Cellectar management will be meeting with investors and discussing the Company’s...

2M ago

CLRB

Cellectar Biosciences Earnings Call: Progress Amid Challenges

Cellectar Biosciences Inc (($CLRB)) has held its Q2 earnings call. Read on for the main highlights of the...

2M ago

CLRB

CLRB FAQ

What was Cellectar Biosciences’s price range in the past 12 months?

Cellectar Biosciences lowest stock price was $3.17 and its highest was $66.00 in the past 12 months.

What is Cellectar Biosciences’s market cap?

Cellectar Biosciences’s market cap is $10.69M.

When is Cellectar Biosciences’s upcoming earnings report date?

Cellectar Biosciences’s upcoming earnings report date is Mar 18, 2026 which is in 128 days.

How were Cellectar Biosciences’s earnings last quarter?

Currently, no data Available

Is Cellectar Biosciences overvalued?

According to Wall Street analysts Cellectar Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cellectar Biosciences pay dividends?

Cellectar Biosciences does not currently pay dividends.

What is Cellectar Biosciences’s EPS estimate?

Cellectar Biosciences’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cellectar Biosciences have?

Cellectar Biosciences has 3,192,040 shares outstanding.

What happened to Cellectar Biosciences’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Cellectar Biosciences?

Currently, no hedge funds are holding shares in CLRB

Company Description

Cellectar Biosciences

Cellectar Biosciences, Inc. (CLRB) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs for the treatment of cancer. The company specializes in targeted phospholipid ether-drug conjugate (PDC) cancer therapies. Using its proprietary PDC platform, Cellectar aims to deliver effective treatments with minimal side effects by specifically targeting cancer cells and sparing healthy tissue.

Cellectar Biosciences (CLRB) Earnings & Revenues

Historic Earnings Reports

CLRB Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The call highlighted significant progress in regulatory strategies and product pipeline advancements, especially with the potential accelerated approval path for Iopofosine I-131. However, the notable decrease in R&D and administrative expenses and an increased net loss indicate financial challenges. Overall, the sentiment is cautiously optimistic but tempered by financial concerns.View all CLRB earnings summaries

CLRB Stock 12 Month Forecast

Average Price Target

$15.20

▲(348.38% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","26":"$26","49":"$49","72":"$72","95":"$95"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.40</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,26,49,72,95],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.77,6.71076923076923,7.651538461538461,8.592307692307692,9.533076923076923,10.473846153846154,11.414615384615384,12.355384615384615,13.296153846153846,14.236923076923077,15.177692307692308,16.11846153846154,17.05923076923077,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.77,6.495384615384615,7.22076923076923,7.946153846153846,8.67153846153846,9.396923076923077,10.122307692307693,10.847692307692308,11.573076923076922,12.298461538461538,13.023846153846154,13.749230769230769,14.474615384615385,{"y":15.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.77,6.279999999999999,6.789999999999999,7.3,7.81,8.32,8.83,9.34,9.85,10.36,10.87,11.379999999999999,11.89,{"y":12.4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":94.8,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.5,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.8,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.4,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.9,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":45.6,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.97,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.68,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.76,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.93,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.86,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.72,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.77,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >